Wankhede Durgesh, Bontoux Christophe, Grover Sandeep, Hofman Paul
Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, Centre Hospitalier, Université Côte d'Azur, 06002 Nice, France.
Diagnostics (Basel). 2023 Sep 25;13(19):3043. doi: 10.3390/diagnostics13193043.
mutation () is the most frequent point mutation in non-small cell lung cancer (NSCLC) and has been proven to be a predictive biomarker for direct inhibitors in advanced solid cancers. We sought to determine the prognostic significance of in patients with NSCLC using the meta-analytic approach. A protocol is registered at the International Prospective Register for systematic reviews (CRD42022345868). PubMed, EMBASE, The Cochrane Library, and Clinicaltrials.gov.in were searched for prospective or retrospective studies reporting survival data for tumors with compared with either other mutations or wild-type (-). The hazard ratios (HRs) for overall survival (OS) or Disease-free survival (DFS) of tumors were pooled according to fixed or random-effects models. Sixteen studies enrolling 10,153 participants were included in the final analysis. tumors had poor OS [] but similar DFS [HR 2.36, 95% CI 0.64-8.16] compared to tumors. Compared to other mutations, tumors had poor DFS [] but similar OS [HR, 1.03; 95% CI, 0.84-1.26]. Compared to other mutations, high PD-L1 expression (>50%) [] was associated with tumors. is a promising prognostic factor for patients with NSCLC, negatively impacting survival. Prevailing significant heterogeneity and selection bias might reduce the validity of these findings. Concomitant high PD-L1 expression in these tumors opens doors for exciting therapeutic potential.
（）突变是非小细胞肺癌（NSCLC）中最常见的点突变，并且已被证明是晚期实体癌中直接抑制剂的预测生物标志物。我们试图采用荟萃分析方法确定NSCLC患者中（）的预后意义。一项方案已在国际前瞻性系统评价注册库（CRD42022345868）登记。检索了PubMed、EMBASE、Cochrane图书馆和Clinicaltrials.gov.in，以查找报告（）突变肿瘤与其他（）突变或野生型（-）肿瘤生存数据的前瞻性或回顾性研究。根据固定效应或随机效应模型汇总肿瘤总生存期（OS）或无病生存期（DFS）的风险比（HRs）。最终分析纳入了16项研究，共10153名参与者。与（）肿瘤相比，（）肿瘤的OS较差[]，但DFS相似[HR 2.36，95%CI 0.64-8.16]。与其他（）突变相比，（）肿瘤的DFS较差[]，但OS相似[HR，1.03；95%CI，0.84-1.26]。与其他（）突变相比，高PD-L1表达（>50%）[]与（）肿瘤相关。（）是NSCLC患者有前景的预后因素，对生存有负面影响。普遍存在的显著异质性和选择偏倚可能会降低这些发现的有效性。这些肿瘤中同时存在的高PD-L1表达为令人兴奋的治疗潜力打开了大门。
